Lifeline Scientific, Inc Directorate Change (7184G)
2015年3月6日 - 4:01PM
RNSを含む英国規制内ニュース (英語)
TIDMLSIC
RNS Number : 7184G
Lifeline Scientific, Inc
06 March 2015
Lifeline Scientific, Inc.
("Lifeline" or the "Company")
Directorate Change
Lifeline Scientific (AIM: LSIC), the transplantation technology
company, announces that Dr. Steven Mayer, a Non-Executive Director,
has decided not to stand for re-election at the Company's annual
general meeting in June 2015 in order to devote more time to
demands of other business endeavours, and therefore Dr. Mayer will
no longer be a director of the Company from that time.
John Garcia, Chairman of Lifeline, commented: "We would like to
thank Dr. Mayer for his valuable contributions to the Company over
the last twelve years and wish him well for the future."
For further information:
Lifeline Scientific, Inc. www.lifeline-scientific.com
David Kravitz, CEO Tel: +1 847 294 0300
Lisa Kieres, CFO Tel: +1 847 294 0300
Panmure Gordon (UK) Limited Tel: +44 (0)20 7886 2500
Freddy Crossley (Corporate
Finance)
Maisie Atkinson (Corporate
Broking)
Walbrook Tel: +44 (0) 20 7933 8780 or lifeline@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Mike Wort Mob: +44 (0)7900 608 002
About Lifeline Scientific Inc.
Lifeline Scientific, Inc. is a Chicago-based global medical
technology company with regional offices in Brussels and Sao Paulo.
The Company's focus is the development of innovative products that
improve transplant outcomes and lower the overall costs of
transplantation. Its lead product, LifePort Kidney Transporter, is
the global market-leading medical device for hypothermic machine
preservation of donor kidneys. LifePorts and novel solutions
designed for preservation of other organs are in development, with
LifePort Liver Transporter next in line for commercial launch. For
more information please visit www.lifeline-scientific.com
About LifePort Kidney Transporter
Created with the challenges of organ recovery and transport in
mind, LifePort Kidney Transporter is a proprietary medical device
designed to help improve kidney preservation, evaluation and
transport prior to transplantation. It has been widely studied in
clinical trials throughout the world and is the standard of care
for machine preservation of kidneys. Employed by surgeons in over
185 leading transplant programmes in 27 countries, LifePorts have
successfully preserved over 47,000 kidneys indicated for clinical
transplant. For more information please visit
www.organ-recovery.com
About LifePort Liver Transporter
LifePort Liver Transporter is modeled upon the clinically proven
technology platform of LifePort Kidney Transporter and the
Company's early HMP prototype successfully used in clinical
transplant studies by surgeons at New York-Presbyterian
Hospital/Columbia University Medical Center. LifePort Liver
Transporter and the Company's proprietary machine preservation
solution, Vasosol(R), are in the process of US and European
regulatory registrations. The system is designed to help improve
outcomes in liver transplantation by enabling the clinical use of
hypothermic machine perfusion, and has been developed in
consultation with clinical and research teams specializing in liver
transplantation at Columbia University Medical Center and the
University of Chicago. The system employs a rugged, streamlined
ergonomic design for ease of use and transportability from donor
bedside to recipient operating room. For more information please
visit: http://www.organ-recovery.com/pipeline.php
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAFMGGFMKZGKZZ
Lifeline Sci (LSE:LSIC)
過去 株価チャート
から 6 2024 まで 7 2024
Lifeline Sci (LSE:LSIC)
過去 株価チャート
から 7 2023 まで 7 2024